Very low

Life Sciences & Pharmaceuticals

COVID-19 continues to result in an unprecedented focus on innovation and partnerships to develop drugs and vaccines across the sector late into 2021.

Sector trends & challenges

  • Collaboration

    Knowledge sharing and collaboration to develop vaccines between pharma companies has strengthened the UK and Europe’s position in the sector. This may have a positive longer-term impact on the wider sector moving forwards.

  • Long-term investment

    In July 2021 the UK government announced a new ten-year £200m Life Sciences investment programme in order to support and grow the sector. However, there will remain a strong requirement to show value for money for R&D.

  • Regulatory changes

    Concerns remain over potential regulatory challenges following Brexit. A common theme across the majority of sectors is GDPR and there is an increased focus on the use of data (predominantly patient data) across Life Sciences.

Sector rating profile

Life Sciences & Pharmaceuticals

The British pharmaceutical sector has been and continues to be at the centre of global efforts to stop the spread of COVID-19, having developed the first approved vaccine last year. The longer-term implications of the pandemic on the sector may include increased investment in developing new vaccines and antibiotics to increase human resilience to future health emergencies.

COVID-19 has resulted in an unprecedented focus on innovation and partnerships to develop drugs and vaccines, including how to bring to market safely. In addition, there is growing use of technology to restructure pharmaceutical supply chains in light of the pandemic. Knowledge sharing and collaboration to develop vaccines between pharma companies has strengthened the UK and Europe’s position in the sector. This may have a positive longer-term impact on the wider sector moving forwards.

There is likely to be an increase in future investment from national governments and WHO on developing greater pandemic and disease resilience. Building up research and manufacturing capacity has long lead times and there will remain a strong requirement to show value for money for R&D. The UK Government recently announced a new ten-year investment of £200m into Life Sciences in order to support the sector.

Concerns remain over potential regulatory challenges following Brexit and there is an increased focus on the use of data (predominantly patient data) across the sector. Similarly to many industries, the increasing pace of innovation is providing great opportunities for those willing to adapt.

Find Your Expert

Nigel Carr is Interpath Sector Lead for Life Sciences & Pharmaceuticals. For a full list of our senior people with experience in this sector use the button below.

Our senior team